Axovant Sciences (AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix (ZGNX) and Amicus Therapeutics (FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Are there any Clinical trials to help a past abused spouse facial under the rt. Appears sunken inward was choke so bad at one point when she speaks she sounds as if she has male voice it is embrassing for me

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X